Overview

Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.
Phase:
Phase 4
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Treatments:
Lopinavir
Ritonavir